LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | NVP-AEW541 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5675 | 5752 | 0.9866 | 0.9771 |
| SK-BR-3 | NVP-AEW541 | 10 | uM | LJP5 | 72 | hr | 2543 | 3560 | 5752 | 0.6189 | 0.3302 |
| SK-BR-3 | PHA-665752 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5842 | 5752 | 1.0157 | 1.0266 |
| SK-BR-3 | PHA-665752 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5839 | 5752 | 1.0150 | 1.0250 |
| SK-BR-3 | PHA-665752 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5942 | 5752 | 1.0331 | 1.0558 |
| SK-BR-3 | PHA-665752 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5667 | 5752 | 0.9852 | 0.9748 |
| SK-BR-3 | PHA-665752 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5757 | 5752 | 1.0009 | 1.0015 |
| SK-BR-3 | PHA-665752 | 10 | uM | LJP5 | 72 | hr | 2543 | 4377 | 5752 | 0.7610 | 0.5859 |
| SK-BR-3 | PI103 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5153 | 5418 | 0.9512 | 0.9104 |
| SK-BR-3 | PI103 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 4481 | 5418 | 0.8266 | 0.6782 |
| SK-BR-3 | PI103 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 3290 | 5418 | 0.6061 | 0.2613 |
| SK-BR-3 | PI103 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 2057 | 5418 | 0.3794 | -0.1781 |
| SK-BR-3 | PI103 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1694 | 5418 | 0.3125 | -0.3119 |
| SK-BR-3 | PI103 | 10 | uM | LJP6 | 72 | hr | 2543 | 1624 | 5418 | 0.2995 | -0.3382 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4706 | 5752 | 0.8182 | 0.6863 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 4521 | 5752 | 0.7861 | 0.6301 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 4313 | 5752 | 0.7499 | 0.5657 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 4209 | 5752 | 0.7317 | 0.5333 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 3478 | 5752 | 0.6046 | 0.3042 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 72 | hr | 2543 | 2893 | 5752 | 0.5030 | 0.1155 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4310 | 5752 | 0.7493 | 0.5646 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 4320 | 5752 | 0.7511 | 0.5683 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 4271 | 5752 | 0.7425 | 0.5528 |
| SK-BR-3 | GSK 690693 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 4188 | 5752 | 0.7281 | 0.5273 |
| SK-BR-3 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4369 | 5752 | 0.7596 | 0.5834 |